Table 1.
Baseline Characteristics and Serum Hormones of 40 Participants by Treatment Group [Median (25th, 75th Interquartile Range)]
| Acyline + Pla (n = 8) | Acyline + K400 (n = 8) | Acyline + K800 (n = 8) | Acyline + Dut (n = 8) | Acyline + Ana (n = 8) | All Subjects (n = 40) | |
|---|---|---|---|---|---|---|
| Age, y | 24 (21, 35.5) | 22.5 (20, 26) | 22 (20.5, 25.5) | 21.5 (20, 24) | 21.5 (20.5, 24.5) | 22 (20, 26) |
| BMI, kg/m2 | 24.1 (21.9, 26) | 22.5 (21.6, 25.6) | 24 (21.5, 25.3) | 24 (23.6, 26.3) | 25 (24, 27) | 24.3 (22.3, 25.8) |
| Serum hormones | ||||||
| T, ng/mL | 5.2 (4.6, 6.3) | 5.5 (5.2, 6.2) | 5.3 (4.7, 6.3) | 5.4 (4.4, 6.4) | 5.2 (4.2, 5.8) | 5.3 (4.8, 6.2) |
| DHT, ng/mL | 0.5 (0.37, 0.59) | 0.44 (0.35, 0.54) | 0.44 (0.35, 0.53) | 0.5 (0.43, 0.89) | 0.42 (0.3, 0.5) | 0.46 (0.36, 0.56) |
| E2, pg/mL | 28.3 (21.3, 39.6) | 39 (16.5, 65.8) | 39 (23.4, 69.4) | 24 (20.9, 30) | 39.4 (21.1, 51.2) | 28.3 (20.9, 53.9) |
| ADD, ng/mL | 0.76 (0.52, 1.12) | 0.7 (0.57, 1.1) | 0.69 (0.59, 0.76) | 0.75 (0.5, 1.1) | 0.65 (0.6, 0.81) | 0.67 (0.57, 0.95) |
| DHEA, ng/mL | 4.2 (3.3, 6.5) | 3.9 (2.7, 7.1) | 4.6 (2.8. 5.9) | 3.9 (3.2, 6.6) | 3.8 (2.8, 4.4) | 3.9 (2.9, 6.1) |
| 17-OHP, ng/mL | 7.2 (5.9, 9.5) | 6 (4.2, 7.9) | 4.8 (4.2, 6.7) | 6.1 (5.1, 9.1) | 6 (4.6, 9) | 6.1 (4.7, 8.1) |
| LH, IU/L | 4.3 (3.3, 5.2) | 5 (3.1, 6.6) | 5.8 (4.7, 7.4) | 4.7 (4.2, 5.4) | 4.9 (4.2, 6.6) | 4.8 (3.9, 6.4) |
| FSH, IU/L | 2.7 (2.3, 2.9) | 2.3 (1.5, 3.5) | 2.4 (1.7, 2.8) | 2.7 (1.8, 3.0) | 2.3 (1.4, 3) | 2.6 (1.7, 3) |
Abbreviations: Ana, anastrazole 1 mg; Dut, dutasteride 2.5 mg; K400, ketoconazole 400 mg; K800, ketoconazole 800 mg; Pla, placebo.